Resources
Current and Emerging Biomarkers to Advance Clinical Research in Parkinson’s Disease
Parkinson’s disease biomarker research continues to advance with the objectives of enabling earlier detection of neurodegeneration, elucidating disease mechanisms, identifying potential therapeutic targets as well as monitoring disease progression. While many promising biomarkers have been proposed, the ideal biomarker — with adequate sensitivity or specificity — remains elusive.
From α-synuclein to advanced magnetic resonance imaging (MRI) techniques, this webinar will cover both traditional Parkinson’s disease biomarkers and the potential utility of emerging biomarkers, such as microRNA (miRNA), microbiome and multimodal approaches.
Citing longitudinal research studies and recent clinical trials, the featured speakers will share the potential utility of fluid-based biomarkers and imaging biomarkers, discussing how each may help track drug efficacy and advance clinical trials.
Join this webinar to learn how fluid and imaging biomarkers can impact study design and patient selection in Parkinson’s disease clinical trials.
Presenters:
-Robert Martone, Associate Director, Labcorp Drug Development
-Hiba Kazmi, PhD, Biomarker Scientist, IXICO
-Antoniya Todorova, MD, PhD, Medical Director, Labcorp
AAIC 2022
Join us in San Diego and online for AAIC 2022, where the world’s leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer’s disease.
View
AD/PD™ 2022
AD/PD™ 2022 brings a new look and a new chapter in the history of the AD/PD™ series of conferences. By merging together with the AAT-AD/PD™ Advances in Alzheimer’s Therapies Focus Meeting, AD/PD™ is now transformed into an annual meeting, with a continuing focus on the ADVANCES IN SCIENCE & THERAPY of Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
We are excited to provide improved opportunities for international medical and scientific professionals to come together and discuss the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
A central theme of the 2022 conference will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.
CHDI - 17th Annual Huntington's Disease Therapeutics Conference
The conference will cover all aspects of HD drug development, including current and future biomarkers, novel HD therapeutic approaches, the new HD Integrated Staging System, updates on clinical trials including GENERATION HD1, and other presentations informing our understanding of HD pathophysiology.
View
GAP-Net Site Optimization Conference 2022
Join us for a unique opportunity to bring together academic and private sites outside the realm of specific Alzheimer’s disease (AD) and Parkinson’s disease (PD) clinical trials. Meet and network with leadership from clinical trial sites across North America, global pharma sponsors, and many partners in AD and PD clinical trial development. Hear from world-class sites and partners on current development barriers, best practices and strategies and engage in the future of clinical trials.
Attending this conference gives you the opportunity to engage with representatives from research sites, to hear their experiences and feedback first-hand outside the scope of working with them directly on a clinical trial. Attendees may glean site perspectives, research trends, common study barriers and innovative solutions, and share how sponsors can be more responsive to sites to increase success in recruitment and enrolment. We have received positive feedback from industry partners who have attended in the past regarding the value they gained in this “out of office” encounter opportunity.
14th Clinical Trials on Alzheimer's Disease (CTAD)
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.
View
MDS 2021 - International Parkinson and Movement Disorder Society
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.
View
AAIC 2021 - Alzheimer's Association International Conference
Join in-person or virtually for AAIC 2021, where the world’s leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer’s disease.
View89-96 of 142 results